No benefit of hemodiafiltration over hemodialysis in lowering elevated levels of asymmetric dimethylarginine in ESRD patients

Blood Purification

Volumn 24, Issue 5-6, 2006, Pages 439-444

  Kalousová, Marta ^a   Kielstein, Jan T ^c   Hodková, Magdaléna ^a   Zima, Tomáš ^a   Dusilová Sulková, Sylvie ^a   Martens Lobenhoffer, Jens ^b   Bode Boger, Stefanie M ^b  

^a CHARLES UNIVERSITY   (Czech Republic)

^b OTTO VON GUERICKE UNIVERSITY   (Germany)

^c HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

2 Microglobulin; Asymmetric dimethylarginine; Hemodiafiltration; Hemodialysis

Indexed keywords

ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; BETA 2 MICROGLOBULIN; ERYTHROPOIETIN; HYPOCHOLESTEROLEMIC AGENT; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; UREA;

ADULT; AMINO ACID BLOOD LEVEL; ARTICLE; CLINICAL ARTICLE; DYSLIPIDEMIA; FEMALE; HEMODIAFILTRATION; HEMODIALYSIS; HUMAN; HYPERTENSION; KIDNEY FAILURE; MALE; PREDICTION; PRIORITY JOURNAL; PROTEIN DETERMINATION; SAMPLE SIZE; UREA NITROGEN BLOOD LEVEL; URINARY EXCRETION;

ADULT; AGED; ARGININE; BETA 2-MICROGLOBULIN; FEMALE; HEMODIAFILTRATION; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; MIDDLE AGED; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

EID: 33845957682     PISSN: 02535068     EISSN: None     Source Type: Journal    
DOI: 10.1159/000095360     Document Type: Article

References (24)

1. Rabindranath KS, Strippoli GF, Roderick P, Wallace SA, Macleod AM, Daly C: Comparison of hemodialysis, hemofiltration, and acetate-free biofiltration for ESRD: systematic review. Am J Kidney Dis 2005;45:437-447.
2. Kielstein JT, Zoccali C: Asymmetric dimethylarginine: a cardiovascular risk factor and a uremic toxin coming of age? Am J Kidney Dis 2005;46:186-202.
3. Kielstein JT, Bode-Boger SM, Hesse G, et al: Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol 2005;25:1414-1418.
4. Schnabel R, Blankenberg S, Lubos E, et al: Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res 2005;97:e53-e59.
5. Valkonen VP, Laakso J, Paiva H, et al: Asymmetrical dimethylarginine (ADMA) and risk of acute coronary events. Does statin treatment influence plasma ADMA levels? Atheroscler Suppl 2003;4:19-22.
6. Zoccali C, Bode-Boger S, Mallamaci F, et al: Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 2001;358:2113-2117.
7. Kielstein JT, Boger RH, Bode-Boger SM, et al: Low dialysance of asymmetric dimethylarginine (ADMA) - in vivo and in vitro evidence of significant protein binding. Clin Nephrol 2004;62:295-300.
8. Schroder M, Riedel E, Beck W, Deppisch RM, Pommer W: Increased reduction of dimethylarginines and lowered interdialytic blood pressure by the use of biocompatible membranes. Kidney Int Suppl 2001;78:S19-S24.
9. Martens-Lobenhoffer J, Bode-Boger SM: Fast and efficient determination of arginine, symmetric dimethylarginine (SDMA) and asymmetric dimethylarginine (ADMA) in biological fluids by hydrophilic interaction liquid chromatography - electrospray tandem mass spectrometry (HILIC-ESI/MS/MS). Clin Chem 2006;52:488-493.
10. Padrini R, Canova C, Conz P, Mancini E, Rizzioli E, Santoro A: Convective and adsorptive removal of beta2-microglobulin during predilutional and postdilutional hemofiltration. Kidney Int 2005;68:2331-2337.
11. Anderstam B, Katzarski K, Bergstrom J: Serum levels of NG, NG-dimethyl-L-arginine, a potential endogenous nitric oxide inhibitor in dialysis patients. J Am Soc Nephrol 1997;8:1437-1442.
12. Schmidt RJ, Domico J, Samsell LS, et al: Indices of activity of the nitric oxide system in hemodialysis patients. Am J Kidney Dis 1999;34:228-234.
13. Kielstein JT, Boger RH, Bode-Boger SM, et al: Asymmetric dimethylarginine plasma concentrations differ in patients with end-stage renal disease: relationship to treatment method and atherosclerotic disease. J Am Soc Nephrol 1999;10:594-600.
14. MacAllister RJ, Rambausek MH, Vallance P, Williams D, Hoffmann KH, Ritz E: Concentration of dimethyl-L-arginine in the plasma of patients with end-stage renal failure. Nephrol Dial Transplant 1996;11:2449-2452.
15. Bergamini S, Vandelli L, Bellei E, et al: Relationship of asymmetric dimethylarginine to haemodialysis hypotension. Nitric Oxide 2004;11:273-278.
16. Achan V, Broadhead M, Malaki M, et al: Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol 2003;23:1455-1459.
17. Kielstein JT, Impraim B, Simmel S, et al: Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation 2004;109:172-177.
18. Beerenhout CH, Luik AJ, Jeuken-Mertens SG, et al: Pre-dilution on-line haemofiltration vs. low-flux haemodialysis: a randomized prospective study. Nephrol Dial Transplant 2005;20:1155-1163.
19. Donauer J, Schweiger C, Rumberger B, Krumme B, Bohler J: Reduction of hypotensive side effects during online-haemodiafiltration and low temperature haemodialysis. Nephrol Dial Transplant 2003;18:1616-1622.
20. Chan CT, Harvey PJ, Boger R, Pierratos A, Floras JS: Dissociation between the short-term effects of nocturnal hemodialysis on endothelium dependent vasodilation and plasma ADMA. Arterioscler Thromb Vasc Biol 2005;25:2685-2686.
21. Penne EL, Blankestijn PJ, Bots ML, et al: Resolving controversies regarding hemodiafiltration versus hemodialysis: the Dutch Convective Transport Study. Semin Dial 2005;18:47-51.
22. Bode-Boger SM, Muke J, Surdacki A, Brabant G, Boger RH, Frolich JC: Oral L-arginine improves endothelial function in healthy individuals older than 70 years. Vasc Med 2003;8:77-81.
23. Boger RH, Ron ES: L-Arginine improves vascular function by overcoming deleterious effects of ADMA, a novel cardiovascular risk factor. Altern Med Rev 2005;10:14-23.
24. Morimoto H, Nakao K, Fukuoka K, et al: Long-term use of vitamin E-coated polysulfone membrane reduces oxidative stress markers in haemodialysis patients. Nephrol Dial Transplant 2005;20:2775-2782.